Transcranial Electromagnetic Treatment (TEMT) Against Alzheimer's Disease

PHASE1/PHASE2UnknownINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

February 10, 2020

Primary Completion Date

February 28, 2021

Study Completion Date

March 31, 2021

Conditions
Alzheimer's Disease
Interventions
DEVICE

MemorEM

The MemorEM device is self-contained and has been designed for in-home daily electromagnetic treatment in the radiofrequency range to the entire forebrain, allowing for complete mobility and comfort in performing daily activities during treatment. The device has a custom control panel that is powered by a rechargeable battery. This control panel/battery box is worn on the upper arm and wired to specialized emitters in the head cap worn by the subject. Everyday for the 12M treatment period, the subject's caregiver will administer one or two 1-hour treatments (two daily treatments during the first 2M period).

Trial Locations (1)

33609

Axiom Clinical Research of Florida, Tampa

All Listed Sponsors
collaborator

Axiom Clinical Research of Florida

UNKNOWN

collaborator

MegaNano Biotech

UNKNOWN

collaborator

Invicro, Boston

UNKNOWN

collaborator

Left Coast Engineering

UNKNOWN

lead

NeuroEM Therapeutics, Inc.

INDUSTRY

NCT04271163 - Transcranial Electromagnetic Treatment (TEMT) Against Alzheimer's Disease | Biotech Hunter | Biotech Hunter